Completed PHASE2 INTERVENTIONAL 8-arm NCT00792298

Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)

A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK-4305 in Patients With Primary Insomnia

Sponsor: Merck Sharp & Dohme LLC

Conditions Primary Insomnia

Interventions Dose-matched Placebo to Suvorexant Suvorexant

Updated 9 times since 2017 Last updated: Oct 8, 2018 Started: Nov 5, 2008 Primary completion: Dec 26, 2009 Completion: Dec 26, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Primary Insomnia, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2022 [monthly]

Completed PHASE2
Dec 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE2
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Aug 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.